Hsinchu County, Taiwan, Taiwan
Experienced professional with over 10 years in new drug development management, specializing in preclinical and early-phase clinical research. Deep expertise in translational science with a strong focus on oncology and gastrointestinal diseases -2017 Biotechnology Industry-Academia Forum, NCHU, Investigated speaker -2018 Biotechnology Industry, Government and Academic Lectures, Bachelor Program of Biotechnology, NCHU. Investigated speaker -Lin, H.-Y., Kao, Y.-H., Chen, S.-T., Meng, M.*. (2009) Effects of inherited mutations on catalytic activity and structural stability of human glucose-6-phosphate isomerase expressed in Escherichia coli. Biochim. Biophys. Acta. 1794:315-323. -Lin, H.-Y., Yu, C.-Y., Hsu, Y.-H., Meng, M*. (2012) Functional analysis of the conserved histidine residue of Bamboo mosaic virus capping enzyme in the activity for the formation of the covalent enzyme-m7GMP intermediate. FEBS Lett. 586:2326-2331 -Hua-Yang Lin, Jyung-Hurng Liu, Ka-Lik Cheng, Jia-Yun Lin, Ni-Rung Liu, Menghsiao Meng A novel binding of GTP stabilizes the structure and modulates the activities of human phosphoglucose isomerase/autocrine motility factor Biochem Biophys Rep 2015 Apr 30;2:14-22. -You-Sin Jian , Ching-Wen Chen, Chih-An Lin, Hsiu-Ping Yu, Hua-Yang Lin, Ming-Yuan Liao, Shu-Huan Wu, Yan-Fu Lin, Ping-Shan Lai1 Hyaluronic acid–nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo International Journal of Nanomedicine 2017:12 2315–2333 -Chih-An Lin , Hui-Min Ho, Parthiban Venkatesan, Chiung-Yi Huang, Yu-Jhen Cheng, Yu-Hsing Lin, Hua-Yang Lin, Tzu-Yang Chen, Ming-Hsi Huang and Ping-Shan Lai Hyaluronic Acid-Glycine-Cholesterol Conjugate-Based Nanoemulsion as a Potent Vaccine Adjuvant for T Cell-Mediated Immunity Pharmaceutics 2021, 13(10), 1569 -Tzu-Yang Chen, Ching-Li Tseng, Chih-An Lin, Hua-Yang Lin, Parthiban Venkatesan and Ping-Shan Lai Effects of Eye Drops Containing Hyaluronic Acid-Nimesulide Conjugates in a Benzalkonium Chloride-Induced Experimental Dry Eye Rabbit Model Pharmaceutics 2021, 13, 1366. -Louis Lin, Ann Wang, Star Lin, Albert Wu, Eskouhie Tchaparian Anticancer Activity of CA102N in MDA-MB-231 Breast Cancer Cells In Vitro and In Vivo AACR annual meeting 2021 -Therapeutic Efficacy of CA102N in Pancreatic Cancer Hua-Yang Lin, Joy Lin, Kay Chang, Ann Wang, Shuling Tu, Albert Wu, Huey Min Ng, Eskouhie Tchaparian AACR annual meeting, San Diego 2024
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine- tipiracil in Patients with locally advanced or metastatic solid tumors Investigational New Drugs volume 41, pages 25–34 (2023) Anticancer Activity of CA102N in MDA-MB-231 Breast Cancer Cells In Vitro and In Vivo. Louis Lin, Ann Wang, Star Lin, Albert Wu, Eskouhie Tchaparian AACR annual meeting, 2021 CA102N suppresses the growth of mouse colon cancer by inhibiting PI3K pathway and immune modulation. Peiying Yang, Tara Conway, Patrea Rhea, Bo Wei, and Eskouhie Tchaparian AACR annual meeting 2020 Nonclinical Safety Evaluation of CA102N, a Hyaluronic Acid (HA) and Nimesulide (Nim) Conjugate for Colorectal Cancer Treatment. Eskouhie Tchaparian; Louis Lin; Elin Hsu; Ivy Chen; Albert Wu AACR annual meeting, Atlanta 2019 Evaluation of antitumor efficacy of CA102N, H-Nim and hyaluronic acid (HA) conjugate, alone or in combination with 5-fluorouracil (5-FU) in in vivo human colorectal cancer models. Eskouhie Tchaparian, Louis Lin, Elin Hsu, Shuling Tu, Sindy Yin, Ivy Chen, Albert Wu. AACR annual meeting, Chicago, 2018 Hyaluronic acid–nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. International Journal of Nanomedicine 2017:12 2315-2333 The antitumor activity of hyaluronic acid nimuselide-NH2 bioconjugate (CA102N) in human colorectal cancer (CRC). Louis Lin, Alexis Tsu, Shuling Tu, Albert Wu, Min Ng, Patrick Li, Eskouhie Tchaparian AACR annual meeting, Washington DC, 2017. The antitumor activity of hyaluronic acid -nimesulide-NH2 bioconjugate (CA102N) in human colorectal cancer. Lin L, Lin S, Hsiao S, Wu A, Tchaparian E. AACR annual meeting, Philadelphia, PA, 2015
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine- tipiracil in Patients with locally advanced or metastatic solid tumors Investigational New Drugs volume 41, pages 25–34 (2023) Anticancer Activity of CA102N in MDA-MB-231 Breast Cancer Cells In Vitro and In Vivo. Louis Lin, Ann Wang, Star Lin, Albert Wu, Eskouhie Tchaparian AACR annual meeting, 2021 CA102N suppresses the growth of mouse colon cancer by inhibiting PI3K pathway and immune modulation. Peiying Yang, Tara Conway, Patrea Rhea, Bo Wei, and Eskouhie Tchaparian AACR annual meeting 2020 Nonclinical Safety Evaluation of CA102N, a Hyaluronic Acid (HA) and Nimesulide (Nim) Conjugate for Colorectal Cancer Treatment. Eskouhie Tchaparian; Louis Lin; Elin Hsu; Ivy Chen; Albert Wu AACR annual meeting, Atlanta 2019 Evaluation of antitumor efficacy of CA102N, H-Nim and hyaluronic acid (HA) conjugate, alone or in combination with 5-fluorouracil (5-FU) in in vivo human colorectal cancer models. Eskouhie Tchaparian, Louis Lin, Elin Hsu, Shuling Tu, Sindy Yin, Ivy Chen, Albert Wu. AACR annual meeting, Chicago, 2018 Hyaluronic acid–nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. International Journal of Nanomedicine 2017:12 2315-2333 The antitumor activity of hyaluronic acid nimuselide-NH2 bioconjugate (CA102N) in human colorectal cancer (CRC). Louis Lin, Alexis Tsu, Shuling Tu, Albert Wu, Min Ng, Patrick Li, Eskouhie Tchaparian AACR annual meeting, Washington DC, 2017. The antitumor activity of hyaluronic acid -nimesulide-NH2 bioconjugate (CA102N) in human colorectal cancer. Lin L, Lin S, Hsiao S, Wu A, Tchaparian E. AACR annual meeting, Philadelphia, PA, 2015
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine- tipiracil in Patients with locally advanced or metastatic solid tumors Investigational New Drugs volume 41, pages 25–34 (2023) Anticancer Activity of CA102N in MDA-MB-231 Breast Cancer Cells In Vitro and In Vivo. Louis Lin, Ann Wang, Star Lin, Albert Wu, Eskouhie Tchaparian AACR annual meeting, 2021 CA102N suppresses the growth of mouse colon cancer by inhibiting PI3K pathway and immune modulation. Peiying Yang, Tara Conway, Patrea Rhea, Bo Wei, and Eskouhie Tchaparian AACR annual meeting 2020 Nonclinical Safety Evaluation of CA102N, a Hyaluronic Acid (HA) and Nimesulide (Nim) Conjugate for Colorectal Cancer Treatment. Eskouhie Tchaparian; Louis Lin; Elin Hsu; Ivy Chen; Albert Wu AACR annual meeting, Atlanta 2019 Evaluation of antitumor efficacy of CA102N, H-Nim and hyaluronic acid (HA) conjugate, alone or in combination with 5-fluorouracil (5-FU) in in vivo human colorectal cancer models. Eskouhie Tchaparian, Louis Lin, Elin Hsu, Shuling Tu, Sindy Yin, Ivy Chen, Albert Wu. AACR annual meeting, Chicago, 2018 Hyaluronic acid–nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. International Journal of Nanomedicine 2017:12 2315-2333 The antitumor activity of hyaluronic acid nimuselide-NH2 bioconjugate (CA102N) in human colorectal cancer (CRC). Louis Lin, Alexis Tsu, Shuling Tu, Albert Wu, Min Ng, Patrick Li, Eskouhie Tchaparian AACR annual meeting, Washington DC, 2017. The antitumor activity of hyaluronic acid -nimesulide-NH2 bioconjugate (CA102N) in human colorectal cancer. Lin L, Lin S, Hsiao S, Wu A, Tchaparian E. AACR annual meeting, Philadelphia, PA, 2015